A quick look at Mannkind Corp reveals a stock chart with shares moving higher. A lot higher. For me this is a company that's almost too small to analyze fundamentally, but technically it's exploding. The initial time to have bought shares was in mid-August as the price moved above the 50 dma. But if that point was missed, then the retest of the 50 dma in late September was the clue that these shares were moving higher. The final indicator was last Friday as the 50 dma moved above the 200 dma. It's now on the move with very little resistance between here and $20 with an ultimate target near previous highs in the $50s.
MannKind Corp, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is headquartered in Westlake Village, California.
(Summary) (Company) (Chart)
| 9 October 2017 Price $5.33 1yr Target $7.00 Analysts 1 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 31.33% Yield 0.00% 1yr Tot Return 31.33% P/E 3.95 PEG 0.15 Beta 2.91 | EPS (ttm) $1.35 EPS next yr $-0.84 Forward P/E --- EPS next 5yr 26.80% 1yr Price Support --- Market Cap $398.26 Mil Revenues $179.90 Mil Earnings $128.80 Mil Profit Margin 71.59% Quick Ratio 0.60 Current Ratio 0.60 Debt/Equity --- | 1yr RevGR --- 3yr RevGR --- 5yr RevGR --- 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA 140.10% ROE -62.10% |
Print 
PDF
RSS Feed
